VIB1116

Phase 1Small molecule

Amgen

VIB1116 is one of 55 small molecule programs targeting Rheumatic Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatic DiseaseActive, not recruiting

Rheumatic DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

82 competitors in Rheumatic Disease

#DrugCompanyPhaseTrials

Anjeso

Boehringer Ingelheim

Approved

1 2

Oruvail

WWyeth-Lederle Vaccines

Approved

—3

Bextra

TThe Searle Company Limited Pakistan

COVID-19 Vaccine

2 5

Jascayd

Orencia

1 7

Cosentyx

Novartis

Phase 2

1 8

Taltz

Eli Lilly

Phase 2

1 9

Bimzelx

UCB

Phase 2

1 10

Stelara

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatic Disease1 trial

A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases

Completed· Amgen logo

Amgen·Phase 1·NCT04948099·73 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VIB1116. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VIB1116 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VIB1116. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Amgen

VIB1116

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatic Disease1 trial

References

Drug Info

Quick Facts

Related News